General Announcement::Glenmark Pharmaceuticals enters into an Exclusive Licensing Agreement with Yuhan Corporation

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
10-Jan-2019 12:45:28
Status
New
Announcement Sub Title
Glenmark Pharmaceuticals enters into an Exclusive Licensing Agreement with Yuhan Corporation
Announcement Reference
SG190110OTHRJ5T9
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
10/01/2019 10:15:00
Description (Please provide a detailed description of the event in the box below)
Sub: Glenmark Pharmaceuticals enters into an Exclusive Licensing Agreement with Yuhan Corporation for commercializing Investigational Seasonal Allergic Rhinitis Nasal Spray Ryaltris in South Korea

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Attachments

SGX_PR_1001.pdf
Total size =392K